[Intracavernous injections in 1991].
Intracavernous injections have been used for about 10 years for the diagnosis and treatment of erectile insufficiencies. This development has been justified by a better knowledge of the physiology of erection and by the recent use of prostaglandin E1. We have reviewed the information provided by the literature (major journals of urology, medicine and physiology), as well as our experience of erectile insufficiency. Diagnostic intracavernous injections allows ruling out vascular or cavernous causes when the injection is followed by a stiff erection within 10 minutes and for more than 20 minutes, whatever the vasoactive agent used. All the causes of erectile insufficiency can be treated with intracavernous injections if the induced erection allows penetration. Prostaglandin E1 provides the highest response rate with fewer adverse effects, but it is not commonly available at present.
Thiounn
N
N
Clinique Urologique, Hôpital Cochin, Paris.
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D010208:Papaverine / Q000494:pharmacology* / Q000627:therapeutic use; D010409:Penile Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D010410:Penile Erection / Q000187:drug effects* / Q000502:physiology; D011453:Prostaglandins / Q000494:pharmacology* / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D011453:Prostaglandins; D010208:Papaverine
Les injections intra-caverneuses en 1991.